Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carvedilol for systemic hypertension.

M E Heber1, G S Brigden, M P Caruana

  • 1Department of Cardiology, Northwick Park Hospital, Middlesex, England.

Journal of Cardiovascular Pharmacology
|January 1, 1987
PubMed
Summary

Carvedilol, a beta-blocker with vasodilating properties, effectively lowers blood pressure (BP) and heart rate in patients with essential hypertension. This study indicates carvedilol is a promising first-line treatment option with potential benefits for left ventricular function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Theoretical analysis of thermomechanical response for biological skin tissues.

Scientific reports·2026
Same author

Comparative thermoelastic analysis of semiconductors with an external heat source under three theories.

Scientific reports·2025
Same author

Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report.

Journal of medical case reports·2023
Same author

Vomiting, electrolyte disturbance, and medications; the perfect storm for acquired long QT syndrome and cardiac arrest: a case report.

Journal of medical case reports·2022
Same author

Aspergillosis following bronchial artery embolization.

QJM : monthly journal of the Association of Physicians·2020
Same author

Observational study comparing pharmacoinvasive strategy with primary percutaneous coronary intervention in patients presenting with ST elevation myocardial infarction to a tertiary care centre in India.

Journal of postgraduate medicine·2017

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Essential hypertension is a prevalent cardiovascular condition requiring effective management.
  • Beta-blockers are a cornerstone of hypertension therapy, but novel agents with additional properties are sought.
  • Carvedilol combines beta-adrenergic blockade with alpha-adrenergic blockade, offering vasodilating effects.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of carvedilol in treating essential hypertension.
  • To assess the impact of carvedilol on 24-hour ambulatory blood pressure and heart rate.
  • To investigate the effects of carvedilol on left ventricular function during exercise.

Main Methods:

  • A 4-week open-label trial involving 12 patients with essential hypertension.
  • Patients received carvedilol, starting at 25 mg twice daily, with titration to 50 mg twice daily if needed.

Related Experiment Videos

  • Ambulatory blood pressure monitoring, heart rate assessment, and radionuclide ventriculography were performed.

    • Main Results:

    • Carvedilol significantly reduced mean daytime systolic BP by 25 mmHg and diastolic BP by 19 mmHg.
    • Mean heart rate decreased by 22 beats/min.
    • Blood pressure during isometric and dynamic exercise was also significantly lowered, with no adverse effect on left ventricular ejection fraction but a reduction in systolic and diastolic volumes.

    Conclusions:

    • Carvedilol demonstrates significant efficacy in reducing blood pressure and heart rate in patients with essential hypertension.
    • The drug was well-tolerated in this patient cohort.
    • The vasodilating properties of carvedilol may offer advantages for left ventricular function compared to traditional beta-blockers, suggesting its utility as a first-line antihypertensive agent.